miR-22在胃癌中表达与临床病理意义
The Expression and Clinicopathologic Significance of Mir-22 in Gastric Cancer
DOI: 10.12677/WJCR.2019.92009, PDF,    国家自然科学基金支持
作者: 唐 仪：南华大学附属湘潭医院病理科，湖南 湘潭；唐云云：永州职业技术学院基础医学系，湖南 永州；刘 芳, 夏 红, 曾 希, 苏 琦*：南华大学肿瘤研究所，湖南省肿瘤细胞与分子病理学重点实验室，湖南省胃癌研究中心，湖南 衡阳；苏 坚：南华大学附属第二医院病理科，湖南 衡阳
关键词: miR-22；组织芯片；原位杂交；胃癌；临床病理意义；Mir-22； Tissue Microarray； In Situ Hybridization； Gastric Cancer； Clinicopathologic Significance
摘要: 目的：探讨miR-22在人胃癌组织的表达及临床病理意义。方法：采用组织芯片与原位杂交技术检测89例胃癌组织及41例正常组织中miR-22的表达水平。结果：原位杂交结果显示，miR-22胃癌组织中的表达水平较正常胃粘膜组织明显下调(P < 0.01)。在89例胃癌组织中，miR-22的表达水平与患者的临床分期和淋巴结转移呈负相关(P < 0.01)。结论：miR-22在胃癌中表达下调，并与胃癌临床分期以及淋巴结转移相关。
Abstract: Objective: To investigate the expression and clinicopathologic significance of miR-22 in human gastric cancer. Methods: Tissue microarray and in situ hybridization were used to detect the ex-pression level of miR-22 in 89 gastric cancer tissues and 41 normal tissues. Results: In situ hy-bridization showed that the expression level of miR-22 in gastric cancer tissues was significantly down-regulated compared with normal gastric mucosa tissues (P < 0.01), and the expression level of miR-22 in gastric cancer tissues was positively correlated. In 89 cases of gastric cancer, the ex-pression level of miR-22 was negatively correlated with clinical staging and lymph node metastasis (P < 0.01). Conclusion: The expression of miR-22 in gastric cancer was down-regulated and correlated with clinical staging and lymph node metastasis of gastric cancer.
文章引用：唐仪, 唐云云, 刘芳, 苏坚, 夏红, 曾希, 苏琦. miR-22在胃癌中表达与临床病理意义[J]. 世界肿瘤研究, 2019, 9(2): 61-68. https://doi.org/10.12677/WJCR.2019.92009

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
[Google Scholar] [CrossRef] [PubMed]
[2] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
[Google Scholar] [CrossRef] [PubMed]
[3] Tang, W., Xu, P., Wang, H., et al. (2018) MicroRNA-150 Suppresses Triple-Negative Breast Cancer Metastasis through Targeting HMGA2. OncoTargets and Therapy, 11, 2319-2332.
[4] Urbanek, M.O., Nawrocka, A.U. and Krzyzosiak, W.J. (2015) Small RNA Detection by in Situ Hybridization Methods. International Journal of Molecular Sciences, 16, 13259-13286.
[Google Scholar] [CrossRef] [PubMed]
[5] Gualeni, A.V., Volpi, C.C., Carbone, A., et al. (2015) A Novel Semi-Automated in Situ Hybridisation Protocol for Microrna Detection in Paraffin Embedded Tissue Sections. Journal of Clinical Pathology, 68, 661-664.
[Google Scholar] [CrossRef] [PubMed]
[6] Cassidy, A. and Jones, J. (2014) Developments in in Situ Hybridisation. Methods, 70, 39-45.
[Google Scholar] [CrossRef] [PubMed]
[7] Warford, A. (2016) In Situ Hybridisation: Technologies and Their Application to Understanding Disease. Progress in Histochemistry and Cytochemistry, 50, 37-48.
[Google Scholar] [CrossRef] [PubMed]
[8] Saraggi, D., Galuppini, F., Fanelli, G.N., et al. (2018) MiR-21 Up-Regulation in Ampullary Adenocarcinoma and Its Pre-Invasive Lesions. Pathology—Research and Practice, 214, 835-839.
[Google Scholar] [CrossRef] [PubMed]
[9] Iida, M., Hazama, S., Tsunedomi, R., et al. (2018) Overexpression of miR-221 and miR-222 in the Cancer Stroma Is Associated with Malignant Potential in Colorectal Cancer. Oncology Reports, 40, 1621-1631.
[Google Scholar] [CrossRef] [PubMed]
[10] He, X., Chen, S.Y., Yang, Z., et al. (2018) miR-4317 Suppresses Non-Small Cell Lung Cancer (NSCLC) by Targeting Fibroblast Growth Factor 9 (FGF9) and Cyclin D2 (CCND2). Journal of Experimental & Clinical Cancer Research, 37, 230.
[Google Scholar] [CrossRef] [PubMed]
[11] Cao, M.Q., You, A.B., Zhu, X.D., et al. (2018) miR-182-5p Promotes Hepatocellular Carcinoma Progression by Repressing FOXO3a. Journal of Hematology & Oncology, 11, 12.
[Google Scholar] [CrossRef] [PubMed]
[12] Yang, Y., Jiang, Z., Ma, N., et al. (2018) MicroRNA-223 Targeting STIM1 Inhibits the Biological Behavior of Breast Cancer. Cellular Physiology and Biochemistry, 45, 856-866.
[Google Scholar] [CrossRef] [PubMed]
[13] Johannessen, C., Moi, L., Kiselev, Y., et al. (2017) Expression and Function of the miR-143/145 Cluster in Vitro and in Vivo in Human Breast Cancer. PLoS ONE, 12, e0186658.
[14] Mandal, R., Hardin, H., Baus, R., et al. (2017) Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms. Endocrine Pathology, 28, 345-350.
[Google Scholar] [CrossRef] [PubMed]
[15] Chu, Y.H., Hardin, H., Schneider, D.F., et al. (2017) MicroRNA-21 and Long Non-Coding RNA MALAT1 Are Overexpressed Markers in Medullary Thyroid Carcinoma. Experimental and Molecular Pathology, 103, 229-236.
[16] Zhang, L.X., Jin, W., Zheng, J., et al. (2018) MicroRNA-375 Regulates Proliferation and Apoptosis of Glioma Cancer Cells by Inhibiting CTGF-EGFR Signaling Pathway. Bratislavske Lekarske Listy, 119, 17-21.
[17] Long, M., Zhan, M., Xu, S., et al. (2017) miR-92b-3p Acts as a Tumor Suppressor by Targeting Gabra3 in Pancreatic Cancer. Molecular Cancer, 16, 167.
[Google Scholar] [CrossRef] [PubMed]
[18] Gurvits, N., Autere, T.A., Repo, H., et al. (2018) Proliferation-Associated miRNAs-494, -205, -21 and -126 Detected by in Situ Hybridization: Expression and Prognostic Potential in Breast Carcinoma Patients. Journal of Cancer Research and Clinical Oncology, 144, 657-666.
[Google Scholar] [CrossRef] [PubMed]
[19] Zheng, J.Z., Huang, Y.N., Yao, L., et al. (2018) Elevated miR-301a Expression Indicates a Poor Prognosis for Breast Cancer Patients. Scientific Reports, 8, 2225.
[Google Scholar] [CrossRef] [PubMed]
[20] Uozaki, H., Morita, S., Kumagai, A., et al. (2014) Stromal miR-21 Is More Important than miR-21 of Tumour Cells for the Progression of Gastric Cancer. Histopathology, 65, 775-783.
[Google Scholar] [CrossRef] [PubMed]
[21] Wang, J., Li, Y., Ding, M., et al. (2017) Molecular Mechanisms and Clinical Applications of miR-22 in Regulating Malignant Progression in Human Cancer (Review). International Journal of Oncology, 50, 345-355.
[Google Scholar] [CrossRef] [PubMed]
[22] Xin, M., Qiao, Z., Li, J., et al. (2016) miR-22 Inhibits Tumor Growth and Metastasis by Targeting ATP Citrate Lyase: Evidence in Osteosarcoma, Prostate Cancer, Cervical Cancer and Lung Cancer. Oncotarget, 7, 44252-44265.
[Google Scholar] [CrossRef] [PubMed]
[23] Liu, H., Huang, X. and Ye, T. (2018) MiR-22 Down-Regulates the Pro-to-Oncogene ATP Citrate Lyase to Inhibit the Growth and Metastasis of Breast Cancer. American Journal of Translational Research, 10, 659-669.
[24] Wongjampa, W., Ekalaksananan, T., Chopjitt, P., et al. (2018) Suppression of miR-22, a Tumor Suppressor in Cervical Cancer, by Human Papillomavirus 16 E6 via a p53/miR-22/HDAC6 Pathway. PLoS ONE, 13, e0206644.
[25] Feng, X., Luo, Q., Wang, H., et al. (2018) MicroRNA-22 Suppresses Cell Proliferation, Migration and Invasion in Oral Squamous Cell Carcinoma by Targeting NLRP3. Journal of Cellular Physiology, 233, 6705-6713.
[Google Scholar] [CrossRef] [PubMed]
[26] Xu, M., Li, J., Wang, X., et al. (2018) MiR-22 Suppresses Epithelial-Mesenchymal Transition in Bladder Cancer by Inhibiting Snail and MAPK1/Slug/Vimentin Feedback Loop. Cell Death & Disease, 9, 209.
[Google Scholar] [CrossRef] [PubMed]
[27] Zuo, Q.F., Cao, L.Y., Yu, T., et al. (2015) MicroRNA-22 Inhibits Tumor Growth and Metastasis in Gastric Cancer by Directly Targeting MMP14 and Snail. Cell Death & Disease, 6, e2000.
[28] Jafarzadeh-Samani, Z., Sohrabi, S., Shirmohammadi, K., et al. (2017) Evaluation of miR-22 and miR-20a as Diagnostic Biomarkers for Gastric Cancer. Chinese Clinical Oncology, 6, 16.
[Google Scholar] [CrossRef] [PubMed]
[29] Wang, J., Zhang, H., Zhou, X., et al. (2018) Five Serum-Based miRNAs Were Identified as Potential Diagnostic Biomarkers in Gastric Cardia Adenocarcinoma. Cancer Biomark, 23, 193-203.
[Google Scholar] [CrossRef] 
[30] Huang, Y., Zhu, J., Li, W., et al. (2018) Serum microRNA Panel Excavated by Machine Learning as a Potential Biomarker for the Detection of Gastric Cancer. Oncology Reports, 39, 1338-1346.
[31] Li, S., Liang, X., Ma, L., et al. (2018) MiR-22 Sustains NLRP3 Expression and Attenuates H. Pylori-Induced Gastric Carcinogenesis. Oncogene, 37, 884-896.
[Google Scholar] [CrossRef] [PubMed]
[32] Zhang, S., Zhang, D., Yi, C., et al. (2016) MicroRNA-22 Functions as a Tumor Suppressor by Targeting SIRT1 in Renal Cell Carcinoma. Oncology Reports, 35, 559-567.
[Google Scholar] [CrossRef] [PubMed]
[33] Bao, B., Li, Y., Ahmad, A., et al. (2012) Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents. Current Drug Targets, 13, 1858-1868.
[Google Scholar] [CrossRef] [PubMed]
[34] Mohammadian, F., Pilehvar-Soltanahmadi, Y., Alipour, S., et al. (2017) Chrysin Alters microRNAs Expression Levels in Gastric Cancer Cells: Possible Molecular Mechanism. Drug Research, 67, 509-514.
[Google Scholar] [CrossRef] [PubMed]
[35] Mohammadian, F., Abhari, A., Dariushnejad, H., et al. (2016) Effects of Chrysin-PLGA-PEG Nanoparticles on Proliferation and Gene Expression of miRNAs in Gastric Cancer Cell Line. Iranian Journal of Cancer Prevention, 9, e4190.
[36] Yi, L. and Su, Q. (2013) Molecular Mechanisms for the Anti-Cancer Effects of Diallyl Disulfide. Food and Chemical Toxicology, 57, 362-370.
[37] 唐云云, 唐仪, 刘芳, 等. 二烯丙基二硫上调miR-22通过Wnt-1通路抑制人胃癌细胞增殖与迁移侵袭[J]. 中国药理学通报, 2017, 33(8): 1141-1146.

为你推荐